Revelation Gemini data show ‘broad effect,’ says Roth Capital

Roth Capital analyst Jonathan Aschoff says Revelation Biosciences (REVB) showed data from all Phase 1b PRIME trial patients showing that Gemini was similarly effective in reducing inflammatory cytokine levels, and restoring immunocompetence in chronic kidney disease patient peripheral blood mononuclear cells regardless of background inflammation levels. Gemini significantly reduced the number of elevated cytokines at all measured timepoints after a single dose out to seven days, the analyst tells investors in a research note. Roth says the results show Gemini’s “broad effect.” It keep a Buy rating on the shares with a $16 price target The stock in late day trading is up 6% to $1.20.